STAB (Statera BioPharma) Debt-to-Asset : 0.58 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Statera BioPharma Debt-to-Asset?

Statera BioPharma STAB Debt-to-Asset is 0.58 as of Sep. 2022.

Statera BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $6.72 Mil. Statera BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.69 Mil. Statera BioPharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2022 was $12.75 Mil. Statera BioPharma's debt to asset for the quarter that ended in Sep. 2022 was 0.58.

Statera BioPharma  (OTCPK:STAB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Statera BioPharma Debt-to-Asset Related Terms

Statera BioPharma Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Debt-to-Asset Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Debt-to-Asset
902.50 1.94 0.77

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.17 0.77 0.53 0.56 0.58

STAB vs NRBO, PALI, BLCM: Debt-to-Asset Comparison

For the Biotechnology subindustry, Statera BioPharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Statera BioPharma Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Statera BioPharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Statera BioPharma's Debt-to-Asset falls into.


Statera BioPharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Statera BioPharma's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(4.83 + 11.431) / 21.17
=0.77

Statera BioPharma's Debt-to-Asset for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(6.72 + 0.686) / 12.749
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.58 mean?
Statera BioPharma (STAB) has a Debt-to-Asset of 0.58 as of Sep. 2022. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Debt-to-Asset too high?
Statera BioPharma's current Debt-to-Asset is 0.58.
How does Statera BioPharma's Debt-to-Asset compare to NRBO and PALI?
Statera BioPharma's Debt-to-Asset of 0.58 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Debt-to-Asset is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (STAB) has a current Debt-to-Asset of 0.58. The current Debt-to-Asset is 0.58. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Statera BioPharma (STAB), the current Debt-to-Asset is 0.58 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.